The European Medicines Agency has launched a new, user-focused, interactive website today. The website - which continues on the same address http://www.ema.europa.eu - has been redesigned in direct response to the Agency's research into the types of features and functionality our users would like to see.
New features include:
* Quick medicine searches: Allows you to search for human and veterinary medicines by name and active substance and for herbal medicinal substances by name
* An online library: Enables you to search for all Agency documents currently online through a search on title and date published online.
* Improved navigation: More intuitive labelling and improved organisation of content so that browsing is quicker for all audience groups.
* Audience landing pages: Flags information of specific value to different key users.
* Online calendar and news search: Allows you to keep up to date with the latest news and events at the Agency.
* RSS feeds: Brings information straight to you as soon as it is published online.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.